Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Travere Therapeutics
Biotech
Travere fails to beat off-label blood pressure drug in phase 3
The biotech is undeterred by the failure, outlining plans to talk to the FDA about a path to market based on other aspects of the data set.
Nick Paul Taylor
May 2, 2023 7:00am
FDA’s liver safety request set to delay decision on Travere drug
Oct 14, 2022 10:05am
Vifor doles out $55M upfront to license Travere's asset
Sep 16, 2021 11:41am
FDA sets back Travere's plans for kidney disease drug approval
May 26, 2021 8:10am
Retrophin sheds Shkreli connection with new name: Travere
Nov 17, 2020 10:30am
